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Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted
research efforts in drug development. Therapeutic failure can result from poor permeability of
the blood-brain barrier, heterogeneous drug distribution, and development of resistance.
Elucidation of relationships among such parameters could enable the development of pre-
dictive models of drug response in patients and inform drug development. Complementary
analyses were applied to a glioblastoma patient-derived xenograft model in order to quan-
titatively map distribution and resulting cellular response to the EGFR inhibitor erlotinib. Mass
spectrometry images of erlotinib were registered to histology and magnetic resonance
images in order to correlate drug distribution with tumor characteristics. Phosphoproteomics
and immunohistochemistry were used to assess protein signaling in response to drug, and
integrated with transcriptional response using mRNA sequencing. This comprehensive
dataset provides simultaneous insight into pharmacokinetics and pharmacodynamics and
indicates that erlotinib delivery to intracranial tumors is insufﬁcient to inhibit EGFR tyrosine
kinase signaling.
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G lioblastoma (GBM) is the most common and aggressiveform of primary parenchymal brain tumor1,2. Treatmenttypically involves surgery with concurrent radiotherapy
and chemotherapy; however, prognosis remains poor with a
median survival of just 14–16 months3. While numerous poten-
tial factors contribute to the poor efﬁcacy of otherwise promising
GBM therapies, one major but controversial limitation is het-
erogeneous drug delivery across the blood–brain barrier and the
blood–tumor barrier (hereafter jointly referred to as the BBB).
The BBB provides both physical and biochemical barriers to drug
delivery into normal brain and excludes the majority of oncologic
drugs4. The BBB is generally considered to be disrupted in GBM,
evidenced by accumulation of normally brain-impenetrant
gadolinium (Gd) contrast agent in tumor regions on magnetic
resonance (MR) images5–7. However, the relationship between
imaging-detectable contrast levels and concentrations of small
molecules is not well characterized. Moreover, numerous image-
guided biopsy studies and patterns of failure following gross total
resection of all contrast-enhancing tumor demonstrate, cate-
gorically, that a signiﬁcant portion of all GBM invade tissues
beyond the contrast-enhanced regions6,8–12. Thus, non-uniform
disruption of the BBB may inﬂuence drug delivery throughout
GBM tumors, and the resulting heterogeneous pharmacodynamic
(PD) impact on tumor cell survival may be a critical factor lim-
iting the efﬁcacy of many therapies tested in GBM5,6,13,14.
A common genetic feature of GBM is overexpression of epi-
dermal growth factor receptor (EGFR)3,15. EGFR gene ampliﬁ-
cation occurs in ~40% of GBM, and almost half of these tumors
have additional truncation or point mutations that result in
ligand-independent, high-level constitutive signaling16. Dysregu-
lated EGFR signaling promotes cell proliferation, migration,
invasiveness, and impaired apoptosis17. Erlotinib is a ﬁrst-
generation EGFR tyrosine kinase inhibitor, FDA-approved for
the treatment of non-small cell lung cancer, that has signiﬁcant
activity in adenocarcinoma with activating mutations in the
EGFR kinase domain18,19. Based on the frequency of activation
and importance of EGFR signaling, there has been sustained
interest in evaluating various EGFR inhibitors in GBM. In
pharmacokinetic (PK) studies, the measured concentration of
erlotinib in patient cerebrospinal ﬂuid (CSF) was similar to efﬁ-
cacious concentrations in pre-clinical studies; however, little is
known about how CSF concentrations of erlotinib relate to the
concentrations and heterogeneity of erlotinib distribution in
human brain and tumor tissues20. In pre-clinical models, erloti-
nib has limited distribution into the normal mouse brain, and—
consistent with the concept that hetereogeneous distribution
across the BBB in tumors might limit efﬁcacy—only marginal
activity was observed in clinical trials testing erlotinib in patients
with newly diagnosed or recurrent GBM21–23. Erlotinib is
known to be a substrate for the major efﬂux proteins in the BBB,
P-glycoprotein (P-gp) and breast cancer resistance protein
(BCRP)24–26. The active efﬂux mechanism limiting erlotinib
permeability across an intact BBB, as found in invasive regions of
glioma, may be in part responsible for the lack of adequate
delivery and hence efﬁcacy in GBM. While these clinical studies
demonstrated that erlotinib is not a viable therapy for GBM, there
are numerous other small molecule EGFR inhibitors in devel-
opment with variable distribution across the BBB. Thus, the study
reported herein provides a ‘failure analysis’ to understand the
limitations of erlotinib tumor distribution and to describe a
multi-modal platform that can be used to evaluate and nominate
the most promising drugs for evaluation in clinical testing for
GBM.
The successful evaluation of new treatments for GBM requires
better understanding of the inﬂuence of a number of physiologic
and pharmacologic parameters. Here we present a novel,
multimodal approach to probe these parameters in a GBM
patient-derived xenograft (PDX) model in response to erlotinib.
Brieﬂy, MR imaging T2-weighted (T2W) hyperintense and T1-
weighted Gd contrast-enhanced (T1Gd) image regions allowed
approximate delineation of tumor. Ex vivo tissue sections were
analyzed by matrix-assisted laser desorption/ionization mass
spectrometry imaging (MALDI MSI) to analyze drug and drug
metabolite distribution, and ions identiﬁed as metabolic bio-
markers of the tumor allowed accurate delineation of tumor
regions. Imaging of serial sections by stimulated Raman scattering
(SRS) microscopy produced high resolution images of the dis-
tribution of proteins, lipids and heme, enabling differences in
brain and tumor tissue micro-architecture to be assessed. MS
images were coregistered with the MR images to provide a
comprehensive understanding of drug distribution across various
imaging parameters. The MALDI MSI evaluation of drug levels
was paired with laser capture microdissection (LCM) and sub-
sequent analysis of transcriptional response in regions of het-
erogeneous drug delivery. A comparative study between
intracranial (IC) and ﬂank PDX was included in the experimental
design to evaluate differences in drug delivery and the effect of the
BBB on treatment response at the transcriptional and protein
signaling levels. Collectively, this multimodality analysis estab-
lished a spatially resolved PK-PD model for erlotinib and
demonstrates that this platform is a robust and comprehensive
assessment tool, that could be applied to essentially any novel
therapeutic strategy targeting GBM or other tumor where dif-
ferential drug distribution may be an important factor governing
therapeutic response.
Results
Multimodality analysis for integrated PK and PD. This study
was designed to investigate the distribution of and cellular
response to erlotinib, an EGFR inhibitor, in both ﬂank and IC
GBM PDX models and is outlined in Fig. 1. Mice in both ﬂan-
k and IC groups were dosed with placebo, low (33 mg kg−1) or
high (100 mg kg−1) dose erlotinib, and an additional ﬂank
group was dosed at ultra-low dose (5 mg kg−1). Drug levels in
plasma, brain, and ﬂank tumors were determined by liquid
chromatography–tandem mass spectrometry (LC–MS/MS). Tis-
sue samples were then serially sectioned and processed for
multimodality imaging. Detailed analyses (MRI, 3D MALDI MSI,
histology, SRS microscopy, and mRNA sequencing) were
performed on tissue from one high dosed animal with IC PDX to
provide comparative data for integrated PK and PD. Further
analyses were performed on tissue from animals with ﬂank and
IC PDX under different doses of erlotinib to investigate dose-
dependent response and differences in drug delivery and
distribution.
Heterogeneous drug distribution observed by 3D MALDI MSI.
Brain tissue from an animal bearing an IC tumor and dosed with
100 mg kg−1 erlotinib was harvested and sectioned for multi-
modal imaging. 3D MALDI MSI acquired on a 9.4 T Fourier
transform ion cyclotron resonance (FT-ICR) MS was used to
measure the distribution of drug and metabolite in relation to
endogenous biomolecules. Coronal sections of the tumor region
were taken every 160 µm, as outlined in Fig. 2a, b. Serial sections
were stained with H&E for comparison. Images of ions with m/z
394.1760 (Δppm= 0.25) (Fig. 2b and Supplementary Figure 1)
indicate that the parent drug (erlotinib) is distributed with higher
intensity in the highly cellular tumor regions compared with
normal brain parenchyma. The drug is not distributed homo-
geneously through tumor, but instead appears with varied
intensity in the x, y, and z dimensions. Images of ions with m/z
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616.1770 (Δppm= 0.49) correspond to heme (Fig. 2b); images of
heme have previously been shown to mark the vasculature27.
Overlaid images of erlotinib and heme show low colocalization
between the blood vessels and the drug over the full tissue sec-
tions including both tumor and healthy brain (Fig. 2b, c and
Supplementary Table 1). Both the parent drug and one of its
metabolites (M13/M14)27,28 were detected with higher intensity
in the tumor compared with non-tumor tissue, suggesting that
the BBB is disrupted to a greater degree within tumor regions.
The parent drug was detected with ~10-fold higher intensity than
the metabolite (Supplementary Figure 2).
3D MALDI MS ion images are shown for erlotinib, heme, the
active metabolite of erlotinib (M13/M14) and unidentiﬁed ion
with m/z 503.949, which was found to map to the tumor region
by comparison with H&E (see Fig. 2c). The use of internal
MALDI MSI ‘biomarkers’ to map different tissue features can
provide a more accurate comparison than H&E or other staining
techniques because serial sections undergo separate preparation
and are subject to different distortions. Interestingly the parent
and metabolite demonstrated different distributions, with the
metabolite distributed more broadly, than the parent drug, and a
relatively high concentration detected in the lateral ventricles
(Fig. 2c). Co-localization between different ions was measured by
calculating Pearson’s correlation coefﬁcient between pairs of ion
images (for the whole three-dimensional dataset), see Supple-
mentary Table 1. Correlation values range between 0 (indicating
no co-localization/inverse distribution) and 1 (indicating perfect
co-localization). The highest co-localization was observed
between the parent drug and drug metabolite, and both the
parent drug and metabolite showed similar co-localization with
the tumor biomarker, indicating similar speciﬁcity for the target
region.
Comparative analysis of MRI and MALDI MSI. MR images and
3D MALDI images from the same animal were co-registered to
establish the relationships among BBB disruption, drug dis-
tribution, and tumor microenvironment. To assess the distribu-
tion of drug in relation to histology and MR imaging (T1Gd and
T2W MR images), a non-rigid registration was applied to a
reduced MALDI MSI dataset, and erlotinib was mapped to the
aligned coordinates. Overlaid images between drug and T2W MR
images can be seen in Fig. 2d. Registration between the drug ion
image and H&E histology reveals the extent of heterogeneity in
drug distribution within the tumor region (see Supplementary
Figure 3). Regions of high contrast were similar in T1Gd and
T2W MR images, Fig. 2d. Drug signal intensity was highest
within the regions of high contrast in MR images, as measured
using a mask image of three different regions of interest (ROIs)
segmented from T1Gd MR and erlotinib images (Fig. 2d, e). The
low intensity of erlotinib at the invasive margins of the tumor
(beyond contrast enhanced region of MR images) suggests that
signiﬁcant fractions of the tumor cells are underexposed (Fig. 2d).
Taken together, these data indicate that erlotinib drug levels were
elevated but highly variable within the tumor.
High-resolution imaging with SRS microscopy. SRS microscopy
was used to provide high spatial resolution images of chemical
constituents of the brain and tumor microenvironments. SRS
images of protein, lipid and heme (absorption) in serial sections
of brain used for 3D MALDI were acquired (see Fig. 3). Multi-
color SRS images revealed cellular morphologies, and demon-
strated relative levels of different chemical classes in cells and
tissue (Fig. 3b): protein (blue), lipid (green), and heme (red).
Higher levels of protein were detected in the tumor core due to
the highly-packed cancer cell bodies (Fig. 3b–e). At the brain/
tumor boundary, compression or reorganization of the myeli-
nated axon ﬁbers at the tumor margin and cancer cells invading
into the normal brain tissue were observed (Fig. 3f–g). In the
normal brain structure, white matter (high lipid content, in
green) and gray matter (high protein content, in blue) were dis-
tinguished due to the lipid/protein concentration difference
(Fig. 3h–i). Corresponding H&E images (Fig. 3c–i) of serial sec-
tions demonstrated the ability of SRS imaging to provide detailed
spatial and chemical information that could not be provided by
standard histology.
Overlaid, co-registered images of erlotinib (MALDI-MSI) and
SRS images provided a means to investigate drug distribution and
its correlation with the brain tissue structure, morphology, and
chemical components (Fig. 3d–h). Images demonstrated that the
protein rich tumor core contained higher concentrations of the
drug. At the tumor edge (Fig. 3f) an inverse relationship with a
higher lipid content (green) and lower drug content (pink) was
observed. A small, highly localized region of high drug
concentration (pink) was detected in the third ventricle (Fig. 3h).
Together, such initial observations suggest that erlotinib can enter
the tumor core but has limited diffusion across the intact BBB
within regions of normal brain, at the inﬁltrative edge of the
tumor and at the interface between tumor and white matter.
Drug delivery is limited at the invasive tumor edge. Quantita-
tive MALDI MSI was performed to measure absolute con-
centration per pixel in brain and ﬂank tumors under the low and
high doses of erlotinib. A tissue mimetic model29 containing
known quantities of erlotinib was analyzed by MALDI MSI and a
calibration curve was produced (Supplementary Figure 4). The
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Fig. 1 Schematic of multimodal analysis workﬂow for investigation into drug
delivery and response. Two groups of mice were injected with patient-
derived GBM12 tumor cells to establish xenografts either in the ﬂank or
brain. Mice in both groups were treated with either placebo, ultra-low dose
(5 mg kg−1), low dose (33mg kg−1), or high dose (100mg kg−1) erlotinib.
Tissue from mice in each group was analyzed according to the workﬂow
shown in the schematic
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calculated drug concentration in the normal brain, ROI (tumor
regions deﬁned by bisecting k-means clustering of MALDI MSI
data) and ﬂank tumors measured by MALDI MSI were similar to
those measured using an analytical LC–MS/MS assay in normal
and tumor-bearing (ipsilateral to tumor site) tissue, thereby
validating the use of MALDI MSI for erlotinib quantiﬁcation
(Table 1). Quantitative MALDI MSI, was only performed on one
animal in each treatment group, but agreement with LC–MS/MS
measurements (n= 3 for ﬂank, n= 2 for IC) suggests the animals
analyzed by MALDI MSI were representative of the group and
also provides a measure of variation between animals. The brain-
to-plasma ratios of erlotinib obtained in this study were similar to
those previously measured in a rat glioma model.26 Average
concentration of erlotinib (measured by MALDI MSI) in IC PDX
dosed at 33 and 100 mg kg−1 were found to be similar (2354.2
and 2182.3 ng g−1, respectively), with slightly higher concentra-
tion detected in the tumor dosed at 33 mg kg−1 (Table 1). This
could be due to a relatively well vascularized tumor situated closer
to the brain surface in the 33 mg kg−1 dosed animal (Supple-
mentary Figure 5). Further segmentation of the IC tumor into the
core and invading edge (Supplementary Figure 6) reveals ~two-
fold decrease in drug concentration at the edge relative to the
tumor core (at 100 mg kg−1 dose). No difference in drug con-
centration was observed in ﬂank tumors between the core and
edge. The concentration of erlotinib was similar in IC tumors
dosed at 33 and 100 mg kg−1, the average concentrations of
erlotinib in ﬂank tumor was dose-dependent at 2426.8 and
8211.6 ng g−1, for 33 and 100 mg kg−1, respectively. These con-
centration values were next used to correlate dose-related
response detected in further analysis of IC and ﬂank tumors.
Correlation coefﬁcients between drug and heme were calcu-
lated between different image regions (Supplementary Table 2),
providing an indication of the availability of the drug (to tumor
cells), alongside absolute concentration of drug in the region.
Broadly, higher correlation between drug and heme was observed
in IC tumors compared to ﬂank, suggesting that the drug is less
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Fig. 2 Multimodal 3D imaging with MALDI MSI, MRI and H&E, letters ‘L’ and ‘R’ denote left and right sides of the mouse brain. a contrast-enhanced T1-
weighted MR image of mouse with established intracranial tumor. bMALDI MS imaging of serial coronal sections of mouse brain (subset from tumor core
only displayed, see Supplementary Figure 2 for full set of images) with established GBM tumor after treatment with 100mg kg−1 erlotinib (2 h post-dose)
with corresponding H&E staining of adjacent sections (ion images of erlotinib (green, m/z 394.176 ± 0.001) and heme (red, m/z 616.177 ± 0.001) overlaid,
c 3D reconstructions of MALDI ion images collected at 160 μm intervals and imaged at 100 μm spatial resolution, Erlotinib (green, m/z 394.176 ± 0.001),
heme (red, m/z 616.177 ± 0.001), the active metabolite of erlotinib (M13/M14) (cyan, m/z 380.160 ± 0.001), and a tumor biomarker (white, m/z
503.949 ± 0.001), d automatic multimodal non-rigid alignment of erlotinib ion image with T2W and T1Gd MR images of one example section/plane, and
regions of interest (ROI) mask image for normal brain (1), tumor associated drug exclusive of T1Gd hyperintensity (2), and T1Gd hyper intensity (3) were
generated from the registered T1Gd MR and erlotinib ion images, and e boxplot of erlotinib intensity detected in each ROI, where the center line represents
the median, the upper and lower bounds of the box represent the inter-quartile range and the whiskers represent ±1 standard deviation of the mean
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available in the IC tumor, regardless of the relative concentration.
Higher correlation between drug and heme was also observed in
the IC tumor edge compared with corresponding tumor core.
Erlotinib activity is reduced in IC tumors relative to ﬂank.
Tissue immunoﬂuorescence (IF) was used to visualize and rela-
tively quantify EGFR and phosphorylated-EGFR (p-EGFR) in a
further set of IC and ﬂank tumors under placebo, low and high
dose of erlotinib. Hoechst images were used to deﬁne tumor ROIs
based on regions of high cellularity; the tumor was segmented
from normal brain (Supplementary Figure 7), and ﬂank tumors
were segmented from background. Average intensity for total
EGFR and p-EGFR was calculated (see Fig. 4). Total EGFR was
detected with higher relative intensity in IC tumor vs. normal
brain tissue (Supplementary Figure 7). There was no signiﬁcant
difference in total EGFR in IC tumor regions between placebo
and treatment with either low or high dose of erlotinib (t= 1.183,
degrees of freedom (df)= 2, p= 0.358). In ﬂank tumors however,
there was a decrease in the amount of total EGFR after treatment
with high dose erlotinib, relative to placebo (t= 4.213, df= 4,
p= 0.0136). A similar relationship between ﬂank and IC tumors
was observed in relative levels of p-EGFR; on average there was
no change in p-EGFR in IC tumors treated with 100 mg kg−1
erlotinib, relative to placebo (t= 0.162, df= 2 p= 0.8859), how-
ever, heterogeneity in signal intensity was observed in all IC
tumors, which could mask localized regions of response, see
Supplementary Figure 8. A decrease was observed in p-EGFR in
ﬂank tumors after treatment with low (t= 8.562, df= 4, p=
0.001) and high (t= 13.069, df= 4, p= 0.0002) dose erlotinib,
relative to placebo. This result is consistent with a dose–response
relationship where a lower availability of erlotinib in IC tumors
vs. ﬂank results in insufﬁcient suppression of EGFR activity.
A low dose of erlotinib inhibits EGFR in ﬂank. Phosphopro-
teomic analysis was performed on tissue samples from ﬂank
tumors to assess phosphorylation changes in signaling pathways
in response to different doses of erlotinib. Since phosphopro-
teomic analyses require considerable tissue quantities and are
sensitive to post-resection ischemia, our studies were limited to
larger and more quickly resectable ﬂank tumors30. Phosphopro-
teomic analysis identiﬁed 210 unique phosphotyrosine-
containing peptides across the four treatment groups (vehicle,
5, 33 , 100 mg kg−1). Quantifying these phosphorylation sites
across the tumor treatment conditions revealed inter-tumor
heterogeneity in the pre-treatment and ultra-low dose erlotinib
(5 mg kg−1) tumors (see Fig. 5). Upon treatment with erlotinib
cba
ed
hgf
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SRSMS H&E
MS + SRS
Fig. 3 Correlated MALDI MS imaging of the drug (erlotinib) distribution and SRS imaging of the brain tissue morphology. a MALDI MS ion imaging shows
the distribution of Erlotinib across the entire brain tissue section. b SRS imaging shows the chemical constituents (lipid in green; protein in blue; and heme
in red) of the entire serial brain tissue section. c H&E image of another serial brain tissue section corresponding to a and b. d Enlarged overlaid view of
areas marked by the large rectangle in a and b shows distribution of the drug (erlotinib in pink) and tissue morphology (lipid and protein in green and blue,
respectively) of the tumor area, e H&E image corresponding to d. f Enlarged overlaid images of the tumor margin area (marked by rectangle in d) shows
cancer cell invasion into the normal fatty brain structure. g H&E image corresponding to f. h Enlarged overlaid images of the brain structure (marked by
smaller rectangle on a and b featuring the difference between gray (protein rich—blue) and white (lipid rich—green) matter. High concentration of erlotinib
was found in the third ventricle h, with corresponding H&E image shown in i. Scalebars represent lengths as follows: a–c= 1 mm, d and e= 500 µm, f–i=
200 µm
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(33 and 100 mg kg−1), tumor heterogeneity decreased as a con-
sequence of similar responses to signaling inhibition. For these
higher dose conditions, we observed a pronounced inhibition of
the target (EGFR), proximal adaptor proteins (Gab1, Shc1), and
downstream signaling (MAPK1, MAPK3) suggesting that 33 mg
kg−1 is an adequate dose to inhibit EGFR signaling in ﬂank
tumors. Despite the decrease in heterogeneity on treatment,
individual tumors treated with 33 or 100 mg kg−1 erlotinib
demonstrated increased phosphorylation of selected nodes,
potentially indicative of resistance pathways beginning to emerge
in these tumors (Supplementary Dataset 1). Although no con-
sensus resistance pathways were detected in all of the treated
tumors, p130Cas (BCAR1) and PI3K (p110/p85) tyrosine phos-
phorylation were increased in several tumors in response to 5 and
Table 1 Comparison of tissue-to-plasma ratio and concentrations of erlotinib measured by MALDI MSI and LC-MS/MS in IC and
ﬂank tumors and normal brain, whole brain and tumor bearing brain in animals treated with a low dose of erlotinib (33 mg kg−1)
and a high dose (100mg kg−1)
Tumor location/region Low dose (MALDI-MSI)
(ng g−1)
High dose (MALDI-MSI)
(ng g−1)
Low dose (LC–MS/MS) (ng
g−1)
High dose (LC–MS/MS) (ng
g−1)
Flank tumor 2426.8 8211.6 2476.6 ± 1339.9 6267.2 ± 2544.7
Brain tissue
Normal braina 619.3 1082.9 608.4 ± 145.2 3218.8
Tumor only 2354.2 2182.3 NA NA
Tumor core 2411.5 2787.1 NA NA
Tumor edge 2011.2 1446.5 NA NA
Whole brainb NAd NA 471.2 ± 282.6 1337.6 ± 400.4
Tumor-bearing brainc NA NA 719.7 ± 355.0 3677.2
Tissue-to-plasma ratio
Flank tumor NA NA 0.54 ± 0.11 0.63 ± 0.18
Normal brain NA NA 0.11 ± 0.04 0.18 ± 0.08
Whole brain NA NA 0.10 ± 0.02 0.14 ± 0.02
Tumor bearing brain NA NA 0.14 ± 0.08 0.21 ± 0.09
Data are presented as mean (over ROI in MALDI MSI data, n= 1) or mean ± standard deviation (intra-animal LC–MS/MS measurement, n= 2 for brain, n= 3 for ﬂank)
aNon-tumor bearing brain (left hemisphere; contralateral to the injection site) obtained from GBM12 intracranial (orthotopic) xenografts
bBrain tissue obtained from mouse bearing ﬂank GBM12 xenografts
cRight hemisphere (ipsilateral to the injection site) obtained from GBM12 intracranial xenografts
dNA—not analyzed
Placebo 33 mg/kg 100 mg/kg
EG
FR
Placebo 33 mg/kg 100 mg/kg
pE
G
FR
BrainFlank
Hoechst
EGFR
Overlay
Hoechst
Phospho-
EGFR
Overlay
p = 0.0136
p = 0.0002
p = 0.001
a
b
80
60
40
20
Av
er
ag
e 
in
te
ns
ity
0
80
60
40
20
Av
er
ag
e 
in
te
ns
ity
0
EGFR
Flank
Brain
Flank
Brain
Erlotinib dose
Erlotinib dose
p-EGFR
Pla
ce
bo
33
 m
g/k
g
10
0 m
g/k
g
Co
ntr
ol
Pla
ce
bo
33
 m
g/k
g
10
0 m
g/k
g
Co
ntr
ol
Fig. 4 Tissue Immunoﬂuorescence imaging of total EGFR and phosphorylated-EGFR (p-EGFR) in brain and ﬂank tumors. a Images showing total EGFR in
brain and ﬂank tumors (red) overlaid with Hoechst (blue), treated with placebo, low (33 mg kg−1) and high (100mg kg−1) dose erlotinib, and graphs (on
right) showing quantitative analysis EGFR levels over whole tumor region in each treatment group. b Images showing p-EGFR in brain and ﬂank tumors
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33 mg kg−1. To assess the functional relevance of these increased
phosphorylation sites, additional time points or co-treatment, for
instance with PI3K inhibition, would be required.
Dose-dependent transcriptional response in ﬂank and IC.
Transcriptional response to variable erlotinib concentration in
ﬂank tumors was evaluated by mRNA sequencing. We selected
differentially expressed genes (q < .05) from a group comparison
of the different treatment groups (5 mg kg−1 vs. placebo, 33 mg
kg−1 vs. placebo group, and 100 mg kg−1 vs. placebo group) and
utilized Ingenuity comparison analysis to identify canonical
pathways activated and repressed (Z > 1.5 and q < .05). We
observed unique and shared pathway signatures among treatment
groups (Fig. 6a). All erlotinib-treated groups had activated
eukaryotic initiation factor 2 (EIF2), peroxisome proliferator-
activated receptor (PPAR), AMP-activated protein kinase
(AMPK) signaling and decreased actin cytoskeleton and Ephrin B
signaling compared to placebo treated tumors. Additionally, Rho
GTPase activity signature was decreased and RhoGDI signaling
was increased. Speciﬁcally, CDC42, RhoA, and Rac signaling were
decreased in erlotinib-treated tumors compared to placebo. We
observed that treatment with 5 mg kg−1 erlotinib was insufﬁcient
to inactivate EGF, hepatocyte growth factor (HGF), 14-3-3,
protein kinase A, integrin, and phospholipase C signaling path-
ways. Compared to ﬂank tumors with low dose erlotinib, higher
erlotinib doses activated the G1/S cell cycle checkpoint and
interleukin 9 (IL9) pathway, and repressed EGF, cyclin, and death
receptor signaling pathways.
To correlate drug exposure/response ﬁndings from the ﬂank
tumors to IC tumor response, LCM was used to dissect IC tumor
tissue (dosed with 100mg kg−1 erlotinib) into four separate
quadrants (Fig. 6b). MALDI MS ion images of the drug in a serial
tissue section was used to determine the relative concentration of
drug in each quadrant dissected (Fig. 6b, c). Relative drug
concentration per quadrant varied from 100% in quadrant R1 to
75% in quadrant L1 and 64.5% and 61.09% in quadrants R2 and
L2, respectively. Cluster analysis of transcripts from each
quadrant show dose-related response highlighting heterogeneity
in IC drug distribution and associated response. For this analysis,
all genes were taken into account, limiting the differential gene
expression. The overall transcripts from IC tumor dosed with
100 mg kg−1 erlotinib clustered between transcripts from ﬂank
tumors dosed with ultra-low and low dose erlotinib. The centre
portions of IC tumors dosed with 100 mg kg−1 receive similar
concentration of drug as ﬂank tumors dosed with 33 mg kg−1 and
the edge portions of IC tumors receive ~two-fold less, as
determined by MALDI MSI quantiﬁcation. Transcripts from IC
tumors are therefore consistent with the dose–response relation-
ship observed in ﬂank tumors, Fig. 6d.
Integration of phosphoproteomic and mRNA sequencing data.
We have previously shown that correlating phosphoproteomic
data across different tumors enabled the identiﬁcation of acti-
vated signaling networks31; here we applied this same approach to
identify co-regulated networks of phosphorylation sites across
tumors and treatment conditions. Hierarchical clustering analysis
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of the correlation matrix of the 210 tyrosine phosphorylation sites
across tumors yielded a few clusters (Fig. 7a, Supplementary
Dataset 1), including a large, highly correlated cluster for most of
the phosphorylation sites in the middle of the clustergram. This
large cluster demonstrates that, despite the inter-tumor hetero-
geneity, most of the sites were co-regulated across tumors and
treatment conditions. Smaller sub-clusters were also evident
within the data, including a cluster of highly co-regulated sites
comprised of four EGFR phosphopeptides, phosphorylation sites
on the proximal adaptor proteins and direct EGFR substrates
SHC and GAB1, the activation loop phosphorylation sites on the
ERK1 and ERK2 mitogen-activated kinases (MAPK3 and
MAPK1), and a site on ARHGAP35 (p190RhoA). The ERK
MAPKs are known to be directly downstream of EGFR/SHC/
GAB1 activation, and p190RhoA is involved in the EGFR path-
way as well32. Importantly, this sub-cluster demonstrates the
ability of the analysis to extract well-characterized signaling
networks, while other sub-clusters highlight both known and
potentially novel signaling interactions. Using a similar cluster-
ing/correlation-based approach to interrogate the quantitative
mRNAseq data led to the identiﬁcation of two large, anti-
correlated clusters (Fig. 7b) comprised of many smaller sub-
clusters. These large clusters were predominantly deﬁned by sites
that increase or decrease upon EGFR inhibition, and are anti-
correlated due to their differential response to erlotinib.
Quantitative phosphoproteomic and mRNASeq results were
correlated across tumors to attempt to identify co-regulated
networks of signaling and transcripts (Fig. 7c, Supplementary
Dataset 2–3). This analysis was dominated by the direction of the
fold-change on treatment with inhibitor, with most of the
phosphorylation sites and approximately half of the transcripts
decreasing on treatment with erlotinib; these sites and transcripts
were therefore found to correlate, while the other half of the
mRNA data was anti-correlated with both. Interestingly, this
analysis also extracted well-characterized signaling networks,
presumably due to their coordinated response to perturbation.
For instance, a cluster of phosphorylation sites with some of the
strongest correlation/anti-correlation with mRNA includes six
EGFR peptides, three GAB1 peptides, SHC, the ERK 1/2 MAPK
activation loop phosphorylation sites, ARHGAP35, and Annexin
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A1, all well characterized members of the EGFR signaling
network33. As shown in Fig. 7d, phosphorylation sites on given
proteins were not necessarily correlated with their respective
transcripts; for instance the phosphorylation of EGFR, the
proximal adaptor protein GAB1, and the downstream MAPK1
proteins all decrease signiﬁcantly with increasing erlotinib
concentration, while their respective transcript levels either
increase (EGFR, GAB1) or decrease slightly (MAPK1). As this
example demonstrates, acquisition of mRNA and protein
phosphorylation data on the same tumors enables the determina-
tion of whether the change in phosphorylation was likely due to
altered signaling, rather than altered protein expression due to
transcription and translation.
Discussion
Differences in the overall average drug concentration in IC
compared to ﬂank tumors do not sufﬁciently account for the lack
of efﬁcacy of erlotinib in GBM. Overall average drug concentra-
tions of erlotinib in IC tumors at low and high doses were similar
to ﬂank tumors at the low dose. Tissue IF reveals that decreased
levels of p-EGFR were associated with both low and high dose of
erlotinib relative to placebo in ﬂank tumors, but not in IC tumors
with similar erlotinib concentration. Considering these results
together it would appear that the same concentration of drug in
IC and ﬂank tumors did not have the same effect on EGFR.
Closer inspection of MALDI MSI data, however, revealed that
different concentrations of erlotinib were detected in different
regions of the IC tumor; with a higher concentration (~two-fold
higher) measured in the core of the tumor vs. the edge. Fur-
thermore, co-localization between heme and erlotinib images
provided an indication of the availabillty of the drug, i.e., whether
the drug had left the blood vessels and entered brain/tumor tissue.
Higher correlation between drug and heme was observed in IC
tumors compared to ﬂank, which suggested that the drug was less
available in IC tumors. The highest correlation between drug and
heme was observed in the tumor edge, further suggesting that the
drug was least available to the inﬁltrating portion of the tumor.
So, while the tumor core received quantities of drug that had the
desired therapeutic effect in ﬂank, the tumor edge did not. The
combination of lower concentration of drug and low availability
at the tumor edge could be a mechanism of failure of erlotinib.
Registration of SRS microscopy images and MALDI ion images
of erlotinib enabled the distribution of drug to be related to
chemical composition of tissue. Erlotinib showed an almost
inverse relationship with regions of high lipid concentration. The
region of highest intensity in the drug image corresponded with
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the protein-rich tumor core. Lower relative concentrations of
drug were detected in and at the interface with the lipid-rich
regions of white matter. The combination of these two imaging
modalities demonstrates how drug distribution relates to global
chemical content of various tissues and further demonstrates the
limited and heterogeneous nature of drug distribution in the
tumor. Differences in non-speciﬁc binding in different tumor
regions can lead to varying concentrations of free (active) drug
due to region-speciﬁc changes in the fraction unbound. Differ-
ences in the chemical composition of the tissue, such as the tumor
core, peripheral tumor rim, normal brain, and even a tumor in
the ﬂank, may lead to differences in free drug concentrations, and
hence be a factor in determining efﬁcacy34.
Registration of T1Gd and T2W MR images with MALDI ion
images of erlotinib demonstrated that drug distribution over-
lapped with the contrast-enhanced portion of the tumor and the
area of high drug intensity was larger than the contrast-enhanced
portion. This suggested that Gd contrast agent and erlotinib have
different distributions, as would be expected of molecules with
different physico-chemical properties and PK, but which is
mostly disregarded when using contrast enhancement MR to
indirectly evaluate drug distribution. Further, although there were
generally increased levels of drug within the MR image
abnormality, the drug levels were highly variable. This hetero-
geneity in drug delivery to both the highly cellular tumor regions
and the diffusely invaded regions of the brain could provide an
opportunity for tumor cells to escape exposure supporting the
continued tumor progression seen experimentally14.
Activation or inhibition of protein tyrosine phosphorylation
signaling networks should lead to consequent changes in tran-
scriptional networks, which may themselves feed back to alter
phospho-signaling; together, these regulatory networks control
many of the cellular responses to perturbations, including treat-
ment with kinase inhibitors. Integrated phosphoproteomics and
mRNA sequencing data revealed that inhibition of protein sig-
naling pathways did not necessarily correlate with respective
transcription levels. Changes in the phosphorylation of EGFR,
GAB1, and MAPK1 with erlotinib treatment were not correlated
with their respective transcripts, which may suggest that the
change in phosphorylation was due to altered signaling and not
due to transcription and translation. Tissue IF data provided the
bridge between response in ﬂank and IC tumors and showed that
EGFR and p-EGFR were not inhibited at the limited IC drug
exposure.
Analysis of mRNA isolated from four quadrants of the high-
dose IC tumor, suggested that the IC-treated tumors were more
similar to these two lower dose ﬂank cohorts at the transcript
level. While the differential gene expression and ingenuity path-
way for the IC quadrants was limited from having taken all genes
into account (ﬁltering out low abundance genes and batch
sequence effect), the overall result provided evidence that similar
dose-related response was observed in IC and ﬂank tumors
exposed to relatively similar drug levels. It should be noted that
IC tumors were analyzed following a single dose of erlotinib (2 h
post dose), whereas ﬂank tumors were dosed three times over
3 days and sacriﬁced 6 h post ﬁnal dose. After two hours, the
concentration of drug in IC tumors is similar to those measured
in low dose ﬂank (by MALDI MSI) and transcriptomic analysis of
mRNA signatures validates the drug concentration. In addition,
mRNA transcripts change quickly (within 1–2 h) which is con-
sistent with the IC tumor transcript signature being similar to
that from ﬂank tumor at low dose.
Considering the wider implications of this study it is important
to account for model speciﬁc limitations. The integrity of the BBB
in the mouse is clearly a critical factor for assessment of PK; a
recent comparison of BBB permeability in the athymic nude
mouse and an immunocompetent mouse found no difference in
drug (ponatinib, another tyrosine kinase inhibitor) concentration
in plasma and normal brain tissue34. Compromise of the BBB in
brain tumors has been shown to be largely ascribed to tumor cell
secretion of cytokines which leads to localized effects on tight
junctions, as well as other structural features of the BBB35. This
cytokine effect on the BBB has shown to be present in athymic
mice35 suggesting that the PDX model described herein is a
suitable model for PK/PD investigations in GBM. The use of PDX
models requires a deﬁcient immune system and therefore the
inﬂammatory response will be compromised; in future work we
will consider the use of genetically engineered mouse models of
GBM in order to retain and study the effect of an intact immune
system. In addition to the possible issues surrounding the use of
PDX models; in this work we considered a single GBM xenograft
model, it is likely that due to heterogeneity in genotype and
phenotype between different GBM tumors, differences in PK and
PD would be observed in other models.
Overall we propose that signiﬁcant portions of IC PDX tumors
received insufﬁcient drug levels to successfully inhibit EGFR
tyrosine kinase signaling, and that this might be due to both
limitations imposed by the BBB and tissue characteristics. This
conclusion was drawn based on imaging the distribution of
erlotinib in relation to other chemical and functional markers,
and demonstrates the power of the multimodal platform in
establishing relationships between drug PK and PD.
Methods
Animals. All studies involving animals were reviewed and approved by the
Institutional Animal Care and Use Committee at Mayo Clinic. Xenografts were
established in female athymic nude mice (Hsd:athymic Nude-Foxn1nu, ages
6–7 weeks; Envigo, Indianapolis, IN) as previously described36,37. The GBM12
PDX model has been previously described38, full genotypic and phenotypic char-
acterization is available from the Mayo Clinic PDX National Resource (http://www.
mayo.edu/research/labs/translational-neuro-oncology/mayo-clinic-brain-tumor-
patient-derived-xenograft-national-resource). A study into GBM12 IC PDX model
survival with erlotinib treatment demonstrated a modest improvement in overall
survival in mice treated with either 100 or 150 mg kg−1 erlotinib daily for two
weeks or until moribund, compared with a control group, demonstrating the
suitability of this model/drug combination for the study described herein. The
provenance of the PDX models used have been conﬁrmed by short tandem repeat
analysis with a comparison to the original patient tumor or germline DNA sample.
All of the PDX models are maintained by serial heterotopic tumor passage at Mayo
Clinic. Previous testing of these PDX models for Mycoplasma has uniformly been
negative. Mice were stratiﬁed by tumor size and randomized to treatment groups
using the StudyLog database program (http://www.studylog.com/). Mice with
established IC or ﬂank tumors were dosed with a single dose of placebo, 33 or
100 mg kg−1 erlotinib. Two hours post dose mice were euthanized by CO2 inha-
lation and brain and plasma were harvested and ﬂash frozen on dry ice for multi-
modality analysis.
Adaptation phosphoproteomics and mRNA sequencing experiments were
performed on a further set of mice with established ﬂank tumors and were treated
when tumor volume reached 250–350 mm3. Treatments were placebo, 5, 33, or
100 mg kg−1 erlotinib daily for 3 days (total three doses) and 6 h after last dose
mice were euthanized with CO2 inhalation and tumor tissue and plasma were
harvested and ﬂash frozen on dry ice for subsequent analysis. This study included
ﬁve mice per treatment group, the selection of animal number was based on the
feasibility of the downstream analyses (proteomics, RNAseq, MALDI) across
multiple treatment groups. The number of mice used for each analysis is stated for
each method separately. All mice were observed daily by a veterinarian blinded to
the treatment received. The technician performing the tumor measurements was
also blinded to the treatment received.
Sample preparation for MALDI MSI. Brain or ﬂank tumors were dissected and
snap frozen by immersion in liquid nitrogen. Tissues were placed at −25 °C 1 h
before use, and tissue sections were prepared using a Microm HM550 cryostat
(Thermo Scientiﬁc™, Waltham, MA) with the microtome chamber chilled at
−20 °C and the specimen holder at −19 °C. Cryosections of 12-μm thickness were
thaw mounted onto ITO-coated microscopic slides (Bruker Daltonics, Billerica,
MA) for MALDI MSI and onto optical slides for hematoxylin, eosin (H/E) staining,
and Tissue IF. For MALDI MSI, the mounted sections were dried for 15 min in a
desiccator prior to matrix application. 2,5-dihydroxybenzoic acid matrix (DHB,
160 mgmL−1 solution in methanol/0.2% TFA 70:30 vol/vol) was deposited using a
TM-sprayer (HTX imaging, Carrboro, NC) with the following conditions: ﬂow
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rate, 90 μLmin−1; spray nozzle velocity, 1200 mmmin−1; spray nozzle tempera-
ture, 75 °C; nitrogen gas pressure, 10 psi; track spacing, 2 mm; number of passes, 4.
Tissue mimetic sample preparation for quantitative MALDI. 100 μL aliquots of
control mouse brain tissue homogenate were transferred into 7 pre-weighed 1.5 mL
Eppendorf tubes and then each tube was reweighed to provide an accurate mass for
total quantity of homogenate transferred. Based on the weight of the tissue
homogenate in each tube the appropriate concentration of drug standard was
added at concentrations of 50,000, 10,000, 7500, 5000, 2500, 1000, 500 ng g−1
(drug/homogenate). Based on the work of Groseclose et al.29, we developed a 3D
model of their negative mold and printed it using a 3D printer. The negative mold
was ﬁlled with 40% gelatin and placed at −80 °C for 2 h. Once frozen, the assembly
was placed into the chamber of a cryostat held at −40 °C, the negative mold was
removed, and the frozen cylinder of 40% gelatin was separated from the outer tube
by removing the cap and sliding out the 40% gelatin. The 100 μL-spiked tissue
homogenates were then transferred into separate cores in the frozen cylinder of
40% gelatin inside the cryostat chamber. The tissue model was placed at −80 °C for
24 h prior to sectioning. The tissue mimetic model was then sectioned at 12-µm
thickness using a Microm HM550 cryostat and sections were thaw mounted onto
ITO-coated microscopic slides next to the tissue sections for MSI.
MR imaging. Magnetic resonance imaging (MRI) was performed using a Bruker
DRX-300 (300MHz 1 H) 7 T vertical-bore small animal imaging system (Bruker
Biospin, Billerica, MA) similarly to published protocols.39 Throughout imaging,
mice were anesthetized by inhalation of 3–4% isoﬂuorane in air and their
respiratory rate monitored. For T1 weighted imaging, mice were administered Gd
contast agent (Gadavist®) intraperitoneally (i.p.) at a dose of 100 mg kg−1 and
imaged after a 15 minute delay. T2 weighted MRI: RARE pulse sequence, repetition
time (TR)= 1500 ms, echo time (TE)= 70 ms, RARE factor: 16, ﬁeld of view
(FOV): 3.2 × 1.92 × 1.92 cm, matrix: 256 × 128 × 128. T1 weighted MRI: MSME,
TR: 300 ms, TE: 9.5 ms, FOV: 4.0 × 2.0 × 2.0 cm, matrix: 192 × 96 × 96.
MALDI mass spectrometry imaging. Mass spectra were acquired using a 9.4 T
SolariX XR FT-ICR MS (Bruker Daltonics, Billerica, MA) externally calibrated in
electrospray ionization positive ion mode using a tuning mix solution (Agilent
Technologies, Santa Clara, CA). MALDI MS images were acquired with a pixel step
size for the surface raster set 100 µm for 3D imaging of brain sections and 175 µm
for quantitative MALDI MS imaging. Spectra were acquired in positive ion mode
with 250 laser shots accumulated at each location with a range of m/z 380–620 for
erlotinib/M13/M14 metabolites/heme. The laser intensity was set to 15% intensity
to desorb/ionize the drug with a laser frequency of 1000 Hz. MALDI MS images
were displayed and analyzed using FlexImaging 4.0 and SCILS software.
Liquid chromatography–tandem mass spectrometry. Erlotinib hydrochloride
(purity > 99%) was purchased from LC Laboratories (Woburn, MA). [13C6]-erlo-
tinib hydrochloride (purity > 98%) was purchased from Alsachim SAS (Illkirch,
France). Analytical-grade reagents were purchased from Thermo Fisher Scientiﬁc
(Waltham, MA). The erlotinib concentrations in plasma, ﬂank tumor, and brain
resulting from in vivo animal experiments are measured using an reverse-phase
liquid chromatography (Agilent model 1200 separation system; Agilent Technol-
ogies, Santa Clara, CA) interfaced with TSQ Quantum triple quadrupole mass
spectrometer (Thermo Finnigan, San Jose, CA) by operating electrospray in
positive ion mode and spray voltage at 28 V. Brain and ﬂank tumor samples were
homogenized with three tissue volumes of 5% bovine serum albumin (g/v) solution
using a mechanical homogenizer (PowerGen 125; Thermo Fisher Scientiﬁc, Wal-
tham, MA). Liquid–liquid extraction was performed by adding 75 ng of [13C6]-
erlotinib hydrochloride (internal standard), 25-μL aliquot of plasma or 50-μL ali-
quot of tissue homogenate, ten volumes of ice-cold ethyl acetate, and two volumes
of pH 11 buffer (1 mM sodium hydroxide, 0.5 mM sodium bicarbonate). Samples
were vortexed for 5 min, centrifuged at 7500 rpm for 5 min (4 oC), and the organic
layer was dried under nitrogen. The dried drug was reconstituted with 150 µL of
mobile phase (water with 0.1% formic acid:acetonitrile with 0.1% formic acid=
50:50), followed by centrifugation at 14,000 rpm for 5 min (4 oC). 2 µL of the
sample was injected into the Phenomenex Synergi 4 µm polar-RP 80 Å LC column
(75 × 2 mm; Torrance, CA) for chromatographic separation. The mobile phase was
delivered at a ﬂow rate of 0.25 mLmin−1. The retention time was 1.7 min for
erlotinib hydrochloride and [13C6]-erlotinib hydrochloride. The total run time was
5 min. The mass-to-charge ratio (m/z) transitions were 394.44 → 278.00 for erlo-
tinib hydrochloride and 400.20 → 284.10 for [13C6]-erlotinib hydrochloride. The
calibration curve was linear and precise over a range of 1–3000 ng mL−1 (weighting
factor of 1/Y2) with the coefﬁcient of variation of <15%26.
SRS microscopy. The principle and setup of label-free SRS microscope have been
previously described40. Brieﬂy, the SRS microscope was composed of a dual-color
narrow-band laser source (picoEmerald, APE), providing the tunable pump beam
(720–990 nm, pulse width 5–6 ps) and the Stokes beam at a ﬁxed wavelength
(1064 nm, pulse width, 7 ps), and an upright laser-scanning confocal microscope
(FV300, Olympus). The pump and Stokes beams were collinearly combined with a
dichroic mirror, introduced into the microscope via the two-dimensional scanning
head, and then were tightly focused onto the sample using a water-immersion
objective (XL PLAN N 25 ×, NA 1.05; Olympus). Imaging was realized by raster
scanning the laser beams across the sample. Frequency difference between the two
beams determines the Raman shifts to image. By tuning the pump wavelength,
multicolor imaging could be achieved. The laser source was remote controlled
through the RS-232 interface. A single FOV was 350 × 350 μm. Each FOV was
acquired with 512 × 512 pixels in about one second. Tiling imaging was conducted
using an automated stage (MS2000, ASI) with partial overlapping. To realize high-
sensitive SRS imaging free from the laser noise, the Stokes beam was amplitude-
modulated at 10MHz using an electro-optic modulator (EOM, Thorlabs), and the
modulation transferred to the pump beam (i.e., stimulated Raman loss) was
detected using a home-built all-analog lock-in ampliﬁer41. A Si photodiode
detector was used to convert the pump light to electrical signals for detection.
Labview programming (National Instruments Inc.) integrated the whole system for
automatic multi-color and large-tissue image acquisition. Lipids were imaged
(green) at 2854 cm−1 attributed to CH2 stretching vibration from the fatty acid
long chains; proteins were imaged (blue) at 2940 cm−1 mainly attributed to CH3
vibration of the chemical bonds in the amino acids; heme (red) was imaged at
2800 cm−1 due to two-color two-photon absorption. Imaging resolution is
~500 nm. Scale bar, 350 μm.
Tissue IF staining and microscopy. Localization of total and phosphorylated
(Tyr1173) EGFR in tumor sections from ﬂank and brain tumors was examined via
IF staining. Brieﬂy, 8 μm tumor sections were ﬁxed on glass slides in 4% paraf-
ormaldehyde for 10 min at room temperature (RT) and rinsed with PBS. Then, the
cells were permeabilized in PBS containing 0.1% Triton X-100 for 3 min. After
washing with PBS, blocking buffer (5% goat serum/TBS) was applied to block
unspeciﬁc staining for 1 h at RT. The samples were incubated with primary anti-
body (anti-EGFR 1:200 (ab32077) or anti-phospho-EGFR 1:50 (ab32578)) in 5%
goat serum/TBS-0.05% Tween at 4 °C overnight, and subsequently the secondary
antibody (Invitrogen, A11036) was conjugated with Alexa Fluor® 568 and nuclei
were stained with Hoechst. A negative control leaving out the primary antibody
was included. Fluorescence images were acquired using a Zeiss Observer Z.1
microscope equipped with ×20 Plan-APOCHROMAT lens and AxioCam MR3
camera. Fluorescence images of Hoechst and EGFR/p-EGFR were acquired using a
ﬂuorescence light source (X-Cite Series 120Q) and excitation/emission wavelengths
at 365/445 and 554/581 nm, respectively. Exposure times were optimized visually
and ﬁxed at 329 µs for EFGR and p-EGFR, and 24 µs for Hoechst. Images were
processed using Zen Pro 2012 (Blue Edition) and ImageJ. Images of the entire
tissue section (brain or ﬂank tumor) were acquired and subsequently ROI were
created manually using Hoechst images to segment the tumor region in brain and
the full ﬂank tumor. ROIs were transferred to EGFR/p-EGFR and average intensity
over the whole tumor region was calculated (n= 3 per treatment group ﬂank
tumors, n= 2 per treatment group IC tumors). Statistical signiﬁcance was tested
using an unpaired, two-tailed t-test. The species reactivity for anti-p-EGFR is
human (http://www.abcam.com/egfr-phospho-y1173-antibody-e124-ab32578.
html) and for anti-total-EGFR is rat, mouse, and human (http://www.abcam.com/
egfr-antibody-e235-ab32077.html).
Automatic multi-modal non-rigid image registration. The MALDI MSI data-
cube was non-linearly aligned to both H&E histology and MRI using the automatic
t-distributed stochastic neighbor embedding (t-SNE) based registration method42.
Brieﬂy, the dimensionality reduction method of the t-SNE43 was ﬁrst used to
project the hyper-dimensional MALDI MSI datacube into a 3D space for which
coordinates represent t-SNE features. Those 3D t-SNE features were spatially
organized as such each t-SNE feature represents an image that was used to feed a
color channel in a L*a*b* color system, and the resultant combined image is called
t-SNE image. Of note, the spectra were projected while preserving their local
characteristics, in a single map representation in 3D space, based on their pairwise
similarities in which similar spectra were projected close to each other whereas
dissimilar ones were projected far apart. This translates to forming molecularly
distinct structures in the t-SNE image and thus establish spatial correspondences
that would guide the registration with other structure/anatomy-rich images, such
as histology and MRI.
The t-SNE image was then non-linearly aligned to its corresponding 2D MR
image. A 2D MR image was manually selected from the MRI volume at similar
location to that of a MALDI section. In this alignment process, the t-SNE image
was ﬁrst linearly warped using Afﬁne transformation (T_A) to capture global
differences (translation, rotation, scaling, and shearing), and then non-linearly
warped using the BSpline transformation (T_B) to correct for local differences.
And ﬁnally, each m/z image was transformed using T_A and T_B, respectively, to
be spatially aligned with the MR image. This alignment process was repeated but
after replacing the MR image with the corresponding histological image. The
alignment quality was visually assessed.
Phosphoproteomic analysis. Tumor material (whole ﬂank tumor) was collected
from mice (n= 4 per treatment group: vehicle, 5 mg kg−1 erlotinib, 33 mg kg−1
erlotinib, and 100 mg kg−1 erlotinib) and snap frozen in liquid nitrogen. Tumors
were homogenized by sonication in 8M urea supplemented with 1 mM sodium
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orthovanadate (Na3VO4), 0.1% Nonidet P-40, protease inhibitor cocktail (Roche)
(1 tablet/10 mL), and PhosStop (Roche) (1 tablet/10 mL). Protein concentration
was measured by a bicinchoninic acid (BCA) assay (Pierce) and proteins were
reduced with 10 mM dithiothreitol (DTT) for 1 h at 56 °C, alkylated with 50 mM
iodoacetamide for 1 h at RT, and diluted fourfold with 100 mM ammonium acetate
at pH 8.9. Proteins were digested using trypsin (sequencing-grade, Promega; 1 μg
trypsin:50 μg total protein) overnight at RT. Enzyme activity was quenched by
acidiﬁcation of the samples with acetic acid. The peptide mixture was desalted and
concentrated on a C18 Sep-Pak Plus cartridge (Waters) and eluted with 40%
acetonitrile, 0.1% acetic acid. Organic solvent was evaporated in a SpeedVac
vacuum centrifuge. 400 μg aliquots of each sample were aliquoted and frozen in
liquid nitrogen for 5 min, lyophilized and stored at −80 °C. Tumors were processed
and labeled with tandem-mass tag (TMT)−10-plex Mass Tag Labeling Kits
(Thermo)44. One vehicle-treated and one erlotinib-treated (5 mg kg−1, 33 mg kg−1,
100 mg kg−1) tumor was included in each of a total of two TMT-10-plex analyses.
Thus, allowing them to serve as normalization channel, as well as technical
replicates. For TMT labeling, tumor peptide aliquots (400 μg peptide for each
channel) were resuspended in 100 μL of 70% (vol/vol) ethanol, 30% (vol/vol) 0.5 M
triethylammoniumbicarbonate at pH 8.5, and incubated with TMT reagent
resuspended in 40 μL anhydrous acetonitrile at RT for 1 h. The samples were
concentrated, combined, and concentrated to dryness using a SpeedVac centrifuge.
Phosphopeptides were enriched using phosphotyrosine immunoprecipitation and
immobilized metal ion chromatography (IMAC)44. In brief, dried samples were
resuspended in IP buffer (100 mM Tris–HCl, 1% Nonidet P-40 at pH 7.4) and
incubated with protein G agarose beads conjugated with 12 μg of anti-phospho
tyrosine antibodies: 4G10 (Millipore), PY-100 (Cell Signaling Technologies), and
PT-66 (Sigma) overnight at 4 °C. Due to differences in sequence in preferences of
phosphotyrosine-targeting antibodies45, we combined three different antibodies to
maximize the sequence coverage of different phosphorylated tyrosine-containing
peptides by the immunoprecipitation. Beads were washed with IP buffer and rinse
buffer (100 mM Tris–HCl at pH 7.4) and subsequently peptides were eluted with
100 mM glycine at pH 2.5 for 30 min at RT and acidiﬁed with TFA. Next, phos-
phopeptides were additionally enriched by IMAC using Fe-NTA Agarose beads.
Bound peptides were eluted with 250 mM NaH2PO4 and loaded onto a precolumn
[100 μm ID × 10 cm packed with 10 μm C18 beads (YMC gel, ODS-A, 12 nm, S-
10 μm, AA12S11)], which was rinsed with 0.2 M acetic acid for 10 min before
LC–MS analysis44. Raw mass spectral data ﬁles were loaded into Proteome Dis-
coverer version 1.4.1.14 (DBversion: 79) (Thermo) and searched against the human
SwissProt database (including 20,215 sequences) using Mascot version 2.4 (Matrix
Science). TMT reporter quantiﬁcation was extracted and isotope corrected in
Discoverer. Tandem mass spectra were matched with an initial mass tolerance of
10 ppm on precursor masses and 15 mmu for fragment ions. Cysteine carbami-
domethylation, TMT-labeled lysine, and protein N-terminal were searched as ﬁxed
modiﬁcations. Oxidized methionine, and phosphorylation of serine, threonine, and
tyrosine were searched as variable modiﬁcations. Minimal peptide length was seven
amino acids. Only peptides with an ion score > 20 were included in the ﬁnal
peptide list. Peptide quantiﬁcation was normalized based on median relative pro-
tein quantiﬁcation obtained from a crude peptide analysis to correct for minor
variation in sample amount among TMT channels. For each peptide, relative
quantiﬁcation was represented as a ratio between TMT ion intensities for each
analyzed tumor and the included normalization channel. The protein network was
obtained by using the STRING database (version 10.0)46. All active interaction
sources except text mining were included and to ensure high conﬁdence, a con-
ﬁdence score over 0.9 was required. Further network analysis and visualization
were performed by using the Cytoscape platform (version 2.8)47.
RNA isolation and sequencing. ArcturusXT™ LCM System was used to capture
cells from four regions of the IC tumor section. Total RNA from each captured
region were isolated using The ARCTURUS® PicoPure® RNA Isolation kit
according to manufacturer’s protocol. For ﬂank tumors, total RNA was isolated
using RNAeasy Mini Kit (Qiagen) according to manufacturer’s protocol.
Total RNA (50 ng) for each region was used to generate whole transcriptome
libraries for RNA sequencing using Illumina’s TruSeq RNA Sample Prep Kit
(catalog #FC-122-1001) following the manufacturer’s recommendation. Poly-A
mRNA selection was performed using oligo(dT) magnetic beads, and libraries were
enriched using the TruSeq PCR Master Mix and primer cocktail. Ampliﬁed
products were cleaned and quantiﬁed using the Agilent Bioanalyzer and Invitrogen
Qubit. The clustered ﬂowcell was sequenced on the Illumina HiSeq 2500 for paired
100-bp reads using Illumina’s TruSeq SBS Kit V3 (catalog #FC-401-3001).
Transcriptome alignment and differential expression analysis. Lane level fastq
ﬁles were appended together if they were sequenced across multiple lanes. These
fastq ﬁles were then aligned with STAR 2.3.1 to GRCh37.62 using ensembl.63.
genes.gtf as GTF ﬁle. Changes in transcript expression were calculated with Cuffdiff
2.1.1 in FPKM format using upper-quartile normalization. Clustering was per-
formed using R heatmap.2 package with Euclidean Distance and McQuitty clus-
tering method. Files submitted to the European Nucleotide Archive (ENA).
Clustering of phosphoproteomic and transcriptomic data. All 212 phospho-
peptides detected by mass spectrometry and the subset of 5002 transcripts that are
differentially expressed either in the placebo condition vs. any treatment condition,
or in any of the four control and treatment conditions vs. the other three were
analyzed. Replicate spectrometric measurements from the same tumor were
averaged geometrically before use. A pseudocount of 0.001 FPKM was added to
each transcriptomic measurement, and then the data were normalized to control
tumor 2786 and log-transformed. Pearson correlation coefﬁcients were calculated
for each phosphopeptide and transcript with each other across tumor samples.
Vectors of correlation coefﬁcients within or across classes of measurement were
clustered hierarchically using the Euclidean distance metric, average linkage, and
leaf ordering to maximize the similarity between neighboring leaves using Matlab
version R2017b.
Data availability
The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE partner repository with the dataset iden-
tiﬁer PXD006769. Binary sequence alignment/map (BAM) ﬁles of RNA-seq data
from GBM12 ﬂank and intracranial studies are available from the EMBL-EBI
European Nucleotide Archive (ENA) database - http://www.ebi.ac.uk/ena/ with
accession number PRJEB25377. For the intracranial study, the sample accession
numbers are ERS2269279–ERS22692780 and ERS2272583–ERS2272584. For the
ﬂank study, the sample accession numbers are ERS2280157–ERS2280161 and
ERS2310063–ERS2310074. All other data is available upon request.
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